Jax DiEugenio

Ahead of the 2026 Transplantation & Cellular Therapy Meetings, experts preview data on CAR T-cell therapy efficacy, donor access, and toxicity mitigation.

Real-world, head-to-head data show an improvement in OS with apalutamide plus ADT vs darolutamide plus ADT without docetaxel in mCSPC.

EMA CHMP backs niraparib plus abiraterone with ADT for BRCA1/2-mutant mHSPC, supported by data from the AMPLITUDE study.

Kristen Spencer, DO, discusses how patient goals are shaping first-line treatment selection for metastatic pancreatic cancer.

The emergence of ultra-sensitive ctDNA and CSF testing may help alter monitoring stratedies and adaptive clinical trial designs in metastatic breast cancer.

A meta-analysis found rapid progression and hyperprogression with nivolumab plus ipilimumab in renal medullary carcinoma.

The resubmission of an sBLA of nogapendekin alfa inbakicept plus BCG in BCG-unresponsive, papillary-only NMIBC was discussed with the FDA.

A SEER analysis showed that immune checkpoint inhibitors better improved OS for younger patients vs older patients with advanced renal cell carcinoma.

Andrea Necchi, MD, PhD, discusses data from GDFather-NEO evaluating nivolumab plus visugromab in cisplatin-ineligible MIBC.

Guillermo Garcia-Manero, MD, discusses how updated VERONA trial data showed no OS benefit with venetoclax plus azacitidine vs azacitidine alone in MDS.

The FDA approval of perioperative enfortumab vedotin plus pembrolizumab reshapes curative-intent care for cisplatin-ineligible MIBC.

Melphalan/HDS produced antitumor activity in metastatic uveal melanoma, including a consistent ORR across key subgroups.

The EMA has validated a Type II variation application for trastuzumab deruxtecan plus pertuzumab in first-line HER2-positive metastatic breast cancer.

Micvotabart pelidotin produced early activity in head and neck squamous cell carcinoma as monotherapy and in combination with pembrolizumab.

Nemtabrutinib plus venetoclax showed early activity and manageable safety in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Teclistamab monotherapy significantly improved PFS and OS vs standard-of-care therapy in relapsed/refractory multiple myeloma as early as the second line.

The FDA has accepted an NDA for pimicotinib in tenosynovial giant cell tumor, supported by data from the phase 3 MANEUVER trial.

The FDA will increase its flexibility on CMC requirements for cell and gene therapies to speed their development and better support BLA planning.

FDA announces new CRL for tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease.

ECOG performance status captured only part of the patient experience in advanced gastric or gastroesophageal junction adenocarcinoma.

Bone marrow Immune Atlas in myeloma linked immune system/tumor interactions with disease aggressiveness, potentially improving prognosis and risk stratification.

FDA grants fast track designation to a PARG inhibitor, ETX-19477, for the treatment of BRCA-mutated, platinum-resistant HGSOC.

Phase 2 data showed atezolizumab plus bevacizumab led to limited responses in patients with metastatic colorectal cancer and an MSI-like gene signature.

Post hoc ARAMIS data showed that darolutamide improved MFS and OS in nmCRPC regardless of prior radical prostatectomy or radiotherapy.

In a phase 1b/2 study, copanlisib plus rucaparib was well tolerated and show antitumor activity at the RP2D in mCRPC.

Tafasitamab/lenalidomide added to first-line R-CHOP improved PFS vs R-CHOP alone with no new safety signals in patients with DLBCL.

China’s NMPA approved ipilimumab N01 plus sintilimab as neoadjuvant therapy for stage IIB to III resectable MSI-H/dMMR colon cancer.

Japan’s Ministry of Health, Labour and Welfare has approved tafasitamab plus rituximab and lenalidomide for relapsed/refractory follicular lymphoma.

In case you missed any, read a recap of every episode of OncLive On Air that aired in December 2025.

Brian Wolpin, MD, MPH, is driving advances in early detection, molecular diagnostics, and precision therapies for patients with gastrointestinal cancers